Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on March 24, 2009
Japanese Journal of Clinical Oncology 2009 39(5):332-335; doi:10.1093/jjco/hyp018
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
39/5/332    most recent
hyp018v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ono, A.
Right arrow Articles by Kojima, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ono, A.
Right arrow Articles by Kojima, T.
Related Collections
Right arrow Short Communication
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Activity of S-1 in Advanced or Recurrent Gastric Cancer Patients after Failure of Prior Chemotherapy, Including Irinotecan + Cisplatin or Fluorouracil (Except S-1)

Akira Ono, Narikazu Boku, Yusuke Onozawa, Shuichi Hironaka, Akira Fukutomi, Hiroshi Yasui, Kentaro Yamazaki, Takayuki Yoshino, Keisei Taku and Takashi Kojima

Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan

For reprints and all correspondence: Akira Ono, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimnagakubo, Nagaizumi, Sunto-gun, Shizuoka, Japan. E-mail: a.ono{at}scchr.jp

Received February 6, 2009; accepted February 9, 2009

We retrospectively reviewed to investigate the efficacy and toxicity of monotherapy with S-1 in patients with advanced or recurrent gastric cancer after failure of first-line chemotherapy. Twenty-one patients were evaluated. The median number of treatment cycles was 2 (range 1–19). There were no cases showing either complete or partial response, and 10 patients (47.6%) showed stable disease. The median progression-free survival was 89 days. Sixteen patients (76%) received third-line chemotherapy. The median survival time was 271 days after the initiation of S-1, with a 1-year survival rate of 32%. Hematological toxicities were Grade 4 anemia (9.5%), Grade 3 or 4 neutropenia (9.5%) and leukopenia (4.7%). As for non-hematological toxicities, Grade 3 or 4 diarrhea and anorexia were noted in 9.5% and 14.2% of the patients, respectively. S-1 was found to show no efficacy and cannot be recommended for second-line chemotherapy against gastric cancer.

Key Words: S-1 • gastric cancer • second-line


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.